DiaMedica Therapeutics

DiaMedica announced that its first quarter 2026 financial results will be released after the markets close on Wednesday, May 6th. DiaMedica will host a live conference call on Thursday, May 7th at 8:00 AM EDT / 7:00 AM CDT to provide a business update and discuss financial results. For details: bit.ly/4cTr1zE $DMAC

DiaMedica is pleased to attend the European Stroke Organisation Conference (ESOC), taking place May 6–8 in Maastricht, Netherlands, where leading stroke experts will gather to share findings, exchange ideas, and contribute to shaping the future of stroke care. Visit us at Booth #C40 to connect with our team. #ESOC2026 #VoiceOfStroke #StrokeResearch #ReMEDy2 #InnovationInStrokeCare

DM199 therapy is intended to enhance blood flow and vascular health by increasing available levels of nitric oxide, prostacyclin, and endothelium-derived hyperpolarizing factor—a novel mechanism with potential across #preeclampsia, #fetalgrowthrestriction, and #acuteischemicstroke. Learn more via @pharmaphorum: bit.ly/41IUZ4j $DMAC

DiaMedica is committed to improving the lives of individuals battling serious vascular diseases by developing innovative therapies that reduce ischemia, with an initial focus on #preeclampsia, #fetalgrowthrestriction and #acuteischemicstroke. Learn more: bit.ly/3IOTU57

“We continue to make meaningful progress across our clinical programs, highlighted by further advancement of the DM199 #preeclampsia program," commented Rick Pauls, President & CEO of DiaMedica. For FY 2025 financial results and corporate highlights: bit.ly/4dSfHFW $DMAC

DiaMedica provided a business update and reported financial results for the year ended December 31, 2025. Management will host a conference call tomorrow, March 31st, at 8 AM ET / 7 AM CT to provide a business update and discuss full-year 2025 financial results. For details: bit.ly/4dSfHFW $DMAC

Reminder: DiaMedica will host a live conference call tomorrow, March 31st at 7:00 AM CDT / 8:00 AM EDT to provide a business update and discuss full year 2025 financial results. Web access: bit.ly/4lM38OB Dial In: (646) 357-8766 Conference ID: 4545194 $DMAC

A new review in the Journal of Hypertension explores endothelial triple-pathway vasorelaxation as a key therapeutic target in CKD-associated #ResistantHypertension and highlights DiaMedica's DM199 as a novel approach with the potential to engage all three pathways simultaneously. Read more: bit.ly/4lOAtZj $DMAC

#FetalGrowthRestriction occurs when the fetus doesn't grow as expected, which can lead to premature birth, low birth weight, or stillbirth. With no approved treatments, DiaMedica’s lead candidate, DM199, aims to address the underlying complications of #FGR to improve outcomes. Learn more: bit.ly/3XPSdrP

DiaMedica's FY 2025 financial results will be released after the markets close on Mon., March 30th. DiaMedica will host a live conference call on Tues., March 31st at 7 AM CDT / 8 AM EDT to provide a business update and discuss financial results. For details: bit.ly/3PsqmNx $DMAC

DiaMedica is at #AANN26 in Dallas! We are excited to attend this premier educational event to connect and collaborate with the neuroscience nursing community. Stop by Booth #210 to learn more about the ReMEDy2 trial for #acuteischemicstroke. #InnovationInStrokeCare

DiaMedica Therapeutics’ CEO Rick Pauls discusses how placental ischemia drives preeclampsia, what it means for maternal and fetal outcomes and how ischemic blood flow biology is being studied across pregnancy and stroke in our latest Xtalks Clinical Edge interview at buff.ly/5RVxhSU by @soumya2390. #DiaMedica #IschemicDisease #StrokeResearch #Preeclampsia #KallikreinKininPathway #XtalksClinicalEdge

DiaMedica's DM199 has the potential to offer a novel therapy for #FetalGrowthRestriction, one of the most serious obstetrical complications affecting pregnancies. This represents a potentially significant breakthrough, as #FGR is the leading cause of stillbirth worldwide. bit.ly/3XPSdrP

DiaMedica will be attending the 2026 Neuroscience Nursing Annual Conference, taking place March 21-24 in Dallas. The conference will include educational tracks in mixed neuro, content for advanced practice providers, stroke content, and more. Visit us at Booth #210 to connect with our team and learn about our latest advancements in #strokeresearch. #AANN26

#FetalGrowthRestriction can often occur in patients with #preeclampsia due to reduced blood flow to the placenta, limiting oxygen and essential nutrients to the fetus. DM199 is designed to improve maternal and placental perfusion, representing a novel disease-modifying approach. For more: bit.ly/3XPSdrP

Event Reminder: DiaMedica CEO, Rick Pauls, will deliver a corporate presentation at the Leerink Partners Global Healthcare Conference today, March 11, 2026, at 3:00 p.m. ET. #LeerinkGlobalHealthcare $DMAC

Attending the Barclays 28th Annual Global Healthcare Conference? DiaMedica CEO Rick Pauls will participate in a fireside chat tomorrow, March 10th at 10:00 a.m. ET. #BarclaysHealthcareConference $DMAC

Recent @NPR coverage highlights the urgent need for new treatments for #preeclampsia and underscores the promise of DM199 as a potential therapeutic approach to improve maternal outcomes, if successfully developed and approved. Read the full story here: n.pr/4tGACBg *NPR is an independent third-party media organization. DiaMedica has no affiliation with NPR or its content.

Rick Pauls, President and CEO, comments on receiving Health Canada clearance to initiate the Phase 2 study of DM199 in early-onset #preeclampsia, representing an important regulatory milestone for DiaMedica. For details: bit.ly/4bpjNDT $DMAC

DiaMedica has received Health Canada clearance to initiate its Phase 2 study of DM199 in early-onset #preeclampsia. The Company plans to initiate the trial in 2026 and expand into the US and UK as regulatory clearances are obtained. For more: bit.ly/4bpjNDT $DMAC